Redhawk Wealth Advisors Inc. Takes $1.15 Million Position in Pfizer Inc. $PFE

Redhawk Wealth Advisors Inc. purchased a new stake in Pfizer Inc. (NYSE:PFE) in the 2nd quarter, according to its most recent disclosure with the SEC. The fund purchased 47,497 shares of the biopharmaceutical company’s stock, valued at approximately $1,151,000.

Several other hedge funds and other institutional investors have also modified their holdings of the business. Brighton Jones LLC lifted its position in Pfizer by 1,282.4% in the 4th quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company’s stock valued at $17,677,000 after purchasing an additional 618,117 shares during the last quarter. Revolve Wealth Partners LLC lifted its position in Pfizer by 12.5% in the 4th quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company’s stock valued at $498,000 after purchasing an additional 2,087 shares during the last quarter. Vident Advisory LLC bought a new stake in Pfizer in the 4th quarter valued at about $248,000. Focus Partners Advisor Solutions LLC lifted its position in Pfizer by 20.9% in the 4th quarter. Focus Partners Advisor Solutions LLC now owns 124,346 shares of the biopharmaceutical company’s stock valued at $3,299,000 after purchasing an additional 21,519 shares during the last quarter. Finally, BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp lifted its position in Pfizer by 14.8% in the 4th quarter. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp now owns 1,085,110 shares of the biopharmaceutical company’s stock valued at $28,788,000 after purchasing an additional 139,620 shares during the last quarter. 68.36% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several brokerages recently weighed in on PFE. Bank of America lifted their price objective on shares of Pfizer from $27.00 to $28.00 and gave the company a “neutral” rating in a research report on Wednesday, August 6th. Berenberg Bank dropped their price target on shares of Pfizer from $28.00 to $25.00 and set a “hold” rating on the stock in a research report on Thursday, May 29th. Citigroup boosted their price target on shares of Pfizer from $25.00 to $26.00 and gave the stock a “neutral” rating in a research report on Wednesday, August 6th. Finally, Morgan Stanley boosted their price target on shares of Pfizer from $32.00 to $33.00 and gave the stock an “equal weight” rating in a research report on Wednesday, August 6th. Two equities research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, eleven have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $28.12.

Pfizer Stock Up 0.4%

NYSE PFE opened at $24.16 on Friday. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.16 and a quick ratio of 0.85. The company’s 50 day simple moving average is $24.67 and its 200 day simple moving average is $24.23. Pfizer Inc. has a 12 month low of $20.92 and a 12 month high of $30.43. The company has a market capitalization of $137.33 billion, a P/E ratio of 12.85, a PEG ratio of 0.85 and a beta of 0.55.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 EPS for the quarter, topping analysts’ consensus estimates of $0.58 by $0.20. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The business had revenue of $14.65 billion for the quarter, compared to the consensus estimate of $13.43 billion. During the same period in the previous year, the firm earned $0.60 EPS. The business’s revenue for the quarter was up 10.3% on a year-over-year basis. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. Equities research analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Tuesday, September 2nd. Investors of record on Friday, July 25th were issued a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a dividend yield of 7.1%. The ex-dividend date was Friday, July 25th. Pfizer’s payout ratio is presently 91.49%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.